Immutep Limited

Immutep Limited

PRRUF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$29.47M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Immutep LimitedImmutep Limited-0.5--229%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$29.47 Million
Enterprise Value$-38,354,944.00
Earnings per Share$-0.05
Beta2.2
Outstanding Shares1,473,721,306

Return

Return on Equity-229.50%ROE
Return on Assets-169.59%
Return on Invested Capital-217.89%

Valuation & Multiples

P/E Ratio-0.46P/E Ratio
PEG4.39PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-1.77
Enterprise Value to EBIT0.25
Enterprise Value to Net Income0
Total Debt to Enterprise-0.03
Debt to Equity0.02Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 30, 2026
EPS
-$0.01
Est. -$0.00
Revenue
$10.87 M
Est. $11.60 M

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
-$0.01
Consensus analyst estimate
Revenue Estimate
$1.70 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Immutep Limited

57 employees
CEO: Marc Voigt

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP32...